GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Ether solutions of up to 50 mol% dichloroacetylene are relatively stable, and such solutions can be safely generated by the dehydrochlorination of trichloroethylene. A popular procedure uses potassium hydride as the base:
The Financial Times wrote that the strikes were intended to pressure members of the Venezuelan government into resigning or arranging a handover of power by demonstrating the US military's capability to capture or kill them through targeted strikes. According to The New York Times, "specialists in the laws of war and executive power" stated that Trump had "used the military in a way that had no clear legal precedent or basis". In an interview with Vanity Fair magazine, Susie Wiles, Trump's White House Chief of Staff, told journalist Chris Whipple that Trump would "keep on blowing boats up until Maduro cries uncle." Whipple himself believed the terminology spoke to the possibility of Trump wanting to see regime change, and Wiles described the Vanity Fair article as "a hit piece".
As the nascent polypeptide elongates during proteosynthesis, it passes through the ribosomal tunnel, interacting with the tunnel walls, thus regulating the rate at which it passes through the tunnel. This in turn affect the rate of partial folding, which may already occur at this stage. Short stretches of alpha-helix may form in the inner part of the tunnel and tertiary structure may start forming in the wider tunnel vestibule. As the N-terminus reaches the tunnel exit and is processed by the ribosome-associated protein biogenesis factors, the tertiary structure formed in the tunnel may partially refold. The folding is then completed when the C-terminus is released from the PTC and the protein escapes the tunnel.
Sources: en.wikipedia.org
In addition, Marcos limited his position on the matter through oral statements and avoided issuing an executive order formalizing his stance. There were also unconfirmed reports, including by former Senator Antonio Trillanes, stating that ICC members had already entered the Philippines and were already secretly conducting the investigation. A House probe initiated in April 2024 by Romualdez into a "status quo" agreement in the South China Sea Duterte made during his presidency with Chinese president Xi Jinping was also seen as a "political payback" to Duterte's verbal attacks on Marcos and diminish Duterte's political influence ahead of the 2025 midterm elections. Amidst growing isolation, Duterte found allies who were previously loyal to Marcos. Among them were Marcos' longtime lawyer, Vic Rodriguez, who served as executive secretary in Marcos' first 79 days before resigning; and Marcos' sister, Senator Imee Marcos. On March 11, 2025, Duterte was arrested upon his arrival at Ninoy Aquino International Airport by the Filipino police, which enforced an arrest warrant issued by the International Criminal Court.
=== AP Care Homes === Pickston is the Director of AP Care Homes, a company based in the North West of England which provided residential care for children. The home catered for the needs of children aged 12-16 with emotional and behavioural difficulties. It was a long term solution for vulnerable children. It employed a registered manager, deputy manager and seven full time key workers. Following an inspection on 16 and 17 November 2023, Ofsted concluded AP Care Homes Limited had "serious and/or widespread failures that mean children and young people are not protected or their welfare is not promoted or safeguarded and the care and experiences of children and young people are poor and they are not making progress". Ofsted inspectors said that Pickston had overseen the management of the home but "did not have the skills and experience" to run it in line with children's home regulations. It was also found that Pickston took one child to her home and, after an internal investigation found that “professional boundaries had been blurred”, she allegedly offered to do it again three weeks later. The home closed in December 2023 after Ofsted issued a notice suspending the registration of the home.
In critical illness, inflammation increases tanycyte D2 in the paraventricular nucleus (PVN) of the hypothalamus, leading to local tissue hyperthyroidism. There may also be decreased central D3. This causes negative feedback on the HPT axis, and therefore reduced TRH gene expression in the PVN. This is exemplified by the common NTIS phenotype of low TSH even in the face of peripheral hypothyroidism.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。